Adaptimmune Results and Business Update

  Reaffirming financial guidance; Company funded into early 2024 -

- ASCO data confirms afami-cel potential for synovial sarcoma; BLA submission on-track for Q4 2022 -

- Update from signal-finding Phase 1 SURPASS trial at the September ESMO 2022 Congress -

- Quarterly call to be held today, August 4, 2022, at 8:00 a.m. EDT (1:00 p.m. BST) -

The Company believes that its existing cash, cash equivalents and marketable securities, together with the additional payments under the Strategic Collaboration and License Agreement with Genentech, will fund the Company's current operations into early 2024, as further detailed in the Company's Quarterly Report on Form 10-Q for the three and six months ended June 30, 2022, to be filed with the Securities and Exchange Commission following this earnings release.

Conference Call Information

The Company will host a live teleconference and webcast to provide additional details at 8:00 a.m. EDT (1:00 p.m. BST) today, August 4, 2022. A live webcast of the conference call and replay can be accessed at https://www.gowebcasting.com/12004. Call in information is as follows: (800)-952-5114 (US or Canada) or +1 (416)-406-0743 (International and additional options available HERE). After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (5869059).

https://finance.yahoo.com/news/adaptimmune-reports-second-quarter-financial-113000359.html